Elutia (ELUT) Q2 FY26 earnings call

Elutia Inc. delivered a solid quarter, marked by significant progress in its strategic pivot towards the commercialization of NXT 41X. The company secured substantial non-dilutive capital and advanced its regulatory and manufacturing readiness, while an independent surgeon survey validated strong demand for its lead product. Despite a slight decline in continuing operations revenue and increased R&D leading to a wider adjusted EBITDA loss, management remains focused on the upcoming FDA clearances and full commercial launch, with a clear path to funding through 2028.